Apologies, I found the full year 2023 stuff which has not been posted here in HC, other stuff is missing too, which is strange:
In 2022 EYE had revenues (sales/gross income) of $13.378 mil and a net loss of $7.817 - expenses of $21.195 mil.
In 2023 EYE had revenue of $17 mil and a loss of $17 mil, so expenses of $34 mil, of which there was $6.044 mil recorded as a one off impairment, obviously with normalised expenses of $28 mil.
In 2024 income has been $23.5 mil, so it remains to be seen how much expenses have risen. They are expected to have risen substantially and there will be a significant loss.
*The impairment item was due to the inability of the AlphaRET segment to generate independent cashflows, requiring a cash investment of $6.044 mil, more than the company has available. Not quite a one off non cash item as characterised by TheAnalyst007
EYE Summary (August 2024): Incredibly Undervalued, page-8
Add to My Watchlist
What is My Watchlist?
